産婦人科領域におけるImipenem/Cilastatin sodium (MK-0787/MK-0791) に関する検討

DOI

書誌事項

タイトル別名
  • STUDIES OF IMIPENEM/CILASTATIN SODIUM IN THE FIELD OF OBSTETRICS AND GYNECOLOGY

抄録

Measurement of imipenem/cilastatin sodium (MK-0787/MK-0791) levels in female genital organ tissues after a 30 min. drip infusion of 500 mg/500 mg was carried out to evaluate its usefulness in the obstetrical and gynecological held, and the clinical efficacy of MK-0787/MK-0791 was studied.<BR>1. Concentrations in female genital tissues: Levels of MK-0787 in plasma, uterus, ovary and oviduct were similar to those of MK-0791. The mean peak plasma level was 48 μg/ml at the end of the infusion. Near the end of the infusion, the concentrations in the portio vaginalis and myometrium were about 10 peg and those in the ovary and oviduct were about 13μg/ml, after that, the concentrations decreased to below detectable levels in 5-6 hours. The concentration in exudate of pelvic dead space was about 8μg/ml at 2-3 hours and decreased to undetectable levels within 12 hours.<BR>2. Clinical application: After MK-0787/MK-0791 treatment in a total of 6 patients with adnexitis (1), puerperal intrauterine infection (2), parametritis (1), postoperative pelvic cellulitis (1) and postoperative wound infection (1), clinical results were excellent in 1, good in 2, poor in 2 and unknown in 1 (used of a concomitant drug).<BR>The two patients with a poor response consisted of one patient who had a pelvic cellulitis after an operation for cancer of the cervix and another who had an wound infection after a radical operation for vulvar cancer. These two patients recovered with the concomitant use of MCR.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ